The novel particle-based P2 Plasma Enrichment System achieves the highest reported proteome enrichment with greater reproducibility than any other protein corona-based workflow. The optimized single-well sample preparation, combined with optimized particle surface, stabilizes the labile protein corona and provides exceptional quantitative accuracy.
Through our collaboration with Alamar Biosciences, Biognosys is the provider of choice for NULISAseq™ multiplex assay services tailored for biopharma research. These services are offered from our state-of-the-art facility in Switzerland, equipped with the ARGO™ HT System. These panels are designed for high-sensitivity, multiplexed analysis of plasma and other biofluids, enabling deep insights into complex biological processes and proteins.
Although modern instruments create more data than ever, it also takes longer to get actionable results due to the bottleneck effect of processing these large datasets in traditional computing environments. In response, Spectronaut has been adapted and optimized to unlock the power of proteomics with highly parallelized instances running in the cloud or high-performance computing environments (HPC) to get biological insights faster.
In this White Paper, we walk through the two main strategies for collecting and analyzing mass spectrometry data for discovery proteomics using a label-free quantification (LFQ) approach: data-dependent and data-independent acquisition-based strategies. We discuss the advantages of each in different situations to help you apply the right method for your needs.
The brochure provides you with an overview of the key features and benefits which make Spectronaut the gold-standard software for DIA proteomics analysis. The brochure elaborates on Spectronaut’s easy library generation, high performance, reliability at scale, and all-in-one user experience.
The brochure provides you with an overview of the key features and benefits which make SpectroDive a fast, robust, and seamless solution for targeted proteomics. The brochure elaborates on how SpectroDive enables high-throughput analysis, provides deeper insights into human plasma, and aids integrated panel optimization and biological interpretation.
The brochure provides you with an overview of the key features and benefits which make SpectroMine the most powerful and user-friendly solution for DDA proteomics. The brochure elaborates on SpectroMine’s effortless isobaric labeling quantification, powerful search engine, and all-in-one workflow.
The brochure demonstrates how QuiC provides users with a powerful tool to improve the performance of their mass-spectrometric facility in combination with Biognosys’ indexed Retention Time (iRT) kit. Further, the brochure includes information on how to access QuiC free of charge.
The brochure provides you with an overview of the main features and benefits which make PQ500 the key to the plasma proteome. The brochure elaborates on its accuracy, coverage and depth, as well as different application types. Finally, ordering and customer support information is provided.
The brochure provides an overview of the key features and benefits of our next-generation TrueDiscovery™ platform. In addition, it elaborates on our deep and reproducible proteome, phospho- and immune-proteome quantification and analysis. Finally, it digs into how we identify the most promising and actionable biomarkers for research and clinical decision-making.
The brochure provides an overview of the key features and benefits of our next-generation TrueSignature® platform. In addition, it elaborates on the specificities of our customizable panels for clinical and pharmacodynamics studies.
Our latest white paper highlights our advanced plasma proteomics capabilities, driven by the P2 Enrichment System. The study demonstrates how TrueDiscovery® Plasma Biomarker Discovery services achieve an optimal balance between depth, throughput, and sensitivity, enabling their application in informed clinical decision-making.
Learn more about Biognosys’ proprietary TrueTarget™ platform in our latest brochure. This resource elaborates on how TrueTarget™ identifies the most promising and actionable drug targets to support your research.